---
category: news
title: "Analyzing the Price-to-Earnings Ratio of Citius Pharmaceuticals Inc. (CTXR)"
excerpt: "The 36-month beta value for CTXR is also noteworthy at 1.40. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell."
publishedDateTime: 2023-09-04T08:48:00Z
originalUrl: "https://newsheater.com/2023/09/04/analyzing-the-price-to-earnings-ratio-of-citius-pharmaceuticals-inc-ctxr/"
webUrl: "https://newsheater.com/2023/09/04/analyzing-the-price-to-earnings-ratio-of-citius-pharmaceuticals-inc-ctxr/"
type: article
quality: 22
heat: 22
published: false

provider:
  name: newsheater
  domain: newsheater.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://newsheater.com/wp-content/uploads/2020/01/Image-109.png"
    width: 640
    height: 383
    isCached: true

secured: "9RLLBRU5t5XKU15XysddsMe4Ez6UfrmYItcK/aMN8EbNqaHXMDb6vqIJkkZye79IDRVqaEoqkl++I1liSY9ZO7i4edy309KYSryGg8xW1/ORFHYl+mZBZybDGH5HLEQcf+JKiFTyTZkYwVkzYCNjBWwCPkS1rCCjclthjs9gfF7bEruSHVTsaN0H+ukVvkMnyl/cFLbBiD4Hute3enKSk5FPSa1et8UtBhy/jEJfLen+Rv9uL4PYYdVMs3enygGCieIMJf3UVzoCvJ3R7Oc4/YQHvko8W6ZIGhfiYWsILWYGaP5qpvA04X+8lYwxPsjcjPjdczmmXfqO6qRyB710YjdyDJN8CDwP2+PNyID3DP8=;F83z5WNTRSHVuTQa/+hmoA=="
---

